XML 102 R77.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT INFORMATION | 9 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2025 | Sep. 30, 2024
SEGMENT INFORMATION |  |
SEGMENT INFORMATION | NOTE H – SEGMENT INFORMATION As detailed in Note B above, the Company currently has two reportable segments: (1) Therapeutic DNA Production Services; and (2) DNA Tagging and Security Products and Services. For the three and six-month periods ended June 30 2024, the MDx Testing Services segment is also presented. Resources are allocated by our CEO, COO, CFO and CLO whom, collectively, the Company has determined to be our CODM. Information regarding operations by segment for the three-month period ended June 30, 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | DNA Tagging and | ​ | ​
​ |  | Production |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 160,999 | ​ | $ | 34,263 | ​ | $ | 195,262
Service revenues | ​ |  | 52,070 | ​ | ​ | 57,061 | ​ | ​ | 109,131
Less intersegment revenues | ​ |  | — | ​ |  | — | ​ | ​ | —
Total revenues | ​ | $ | 213,069 | ​ | $ | 91,324 | ​ | $ | 304,393
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 41,528 | ​ | $ | (36,398) | ​ | $ | 5,130
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 1,074,583 | ​ | $ | 119,770 | ​ | $ | 1,194,353
Research and development | ​ | ​ | 705,053 | ​ | ​ | (42,909) | ​ | ​ | 662,144
Total segment operating expenses | ​ | $ | 1,779,636 | ​ | $ | 76,861 | ​ | $ | 1,856,497
Loss from segment operations (a) | ​ | $ | (1,738,108) | ​ | $ | (113,259) | ​ | $ | (1,851,367)
​ Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 218,858 | ​ | $ | — | ​ | $ | 27,786 | ​ | $ | 246,644
Service revenues | ​ |  | 59,901 | ​ | ​ | — | ​ | ​ | 166,244 | ​ | ​ | 226,145
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 325,930 | ​ | ​ | — | ​ | ​ | 325,930
Less intersegment revenues | ​ |  | — | ​ | ​ | (1,200) | ​ | ​ | — | ​ | ​ | (1,200)
Total revenues | ​ | ​ | 278,759 | ​ | ​ | 324,730 | ​ | ​ | 194,030 | ​ | ​ | 797,519
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | ​ | 194,341 | ​ | ​ | (12,260) | ​ | ​ | 63,151 | ​ | ​ | 245,232
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 852,919 | ​ | $ | 165,983 | ​ | $ | 604,955 | ​ | $ | 1,623,857
Research and development | ​ | ​ | 660,515 | ​ | ​ | 52,917 | ​ | ​ | 152,149 | ​ | ​ | 865,581
Total segment operating expenses | ​ | $ | 1,513,434 | ​ | $ | 218,900 | ​ | $ | 757,104 | ​ | $ | 2,489,438
Loss from segment operations (a) | ​ | $ | (1,319,093) | ​ | $ | (231,160) | ​ | $ | (693,953) | ​ | $ | (2,244,206)
​ ​ NOTE H – SEGMENT INFORMATION, continued Information regarding operations by segment for the nine-month period ended June 30, 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | DNA Tagging and | ​ |  |
​ |  | Production |  | Security Products |  | Consolidated
Revenues: | ​ |  |  | ​ |  |  | ​ |  |
Product revenues |  | $ | 668,407 |  | $ | 571,340 | ​ | $ | 1,239,747
Service revenues | ​ | ​ | 159,312 | ​ | ​ | 538,447 | ​ | ​ | 697,759
Clinical laboratory service revenues | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Less intersegment revenues | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Total revenues |  | $ | 827,719 |  | $ | 1,109,787 | ​ | $ | 1,937,506
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit |  | $ | 428,187 |  | $ | 578,700 | ​ | $ | 1,006,887
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 2,931,352 | ​ | $ | 1,155,551 | ​ | $ | 4,086,903
Research and development | ​ | ​ | 2,146,426 | ​ | ​ | 138,293 | ​ | ​ | 2,284,719
Total segment operating expenses | ​ | $ | 5,077,778 | ​ | $ | 1,293,844 | ​ | $ | 6,371,622
(Loss) income from segment operations (a) |  | $ | (4,649,591) |  | $ | (715,144) | ​ | $ | (5,364,735)
​ Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  |
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Product revenues |  | $ | 477,010 | ​ | $ | — | ​ | $ | 470,076 | ​ | $ | 947,086
Service revenues | ​ | ​ | 202,635 | ​ | ​ | — | ​ | ​ | 476,142 | ​ | ​ | 678,777
Clinical laboratory service revenues | ​ | ​ | — | ​ | ​ | 1,004,250 | ​ | ​ | — | ​ | ​ | 1,004,250
Less intersegment revenues | ​ | ​ | — | ​ | ​ | (11,800) | ​ | ​ | — | ​ | ​ | (11,800)
Total revenues |  | $ | 679,645 | ​ | $ | 992,450 | ​ | $ | 946,218 | ​ | $ | 2,618,313
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit |  | $ | 462,464 | ​ | $ | (56,703) | ​ | $ | 366,219 | ​ | $ | 771,980
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 2,371,501 | ​ | $ | 771,499 | ​ | $ | 1,758,312 | ​ | $ | 4,901,312
Research and development | ​ | ​ | 1,834,551 | ​ | ​ | 198,061 | ​ | ​ | 586,215 | ​ | ​ | 2,618,827
Total segment operating expenses | ​ | $ | 4,206,052 | ​ | $ | 969,560 | ​ | $ | 2,344,527 | ​ | $ | 7,520,139
(Loss) income from segment operations (a) |  | $ | (3,743,588) | ​ | $ | (1,026,263) | ​ | $ | (1,978,308) | ​ | $ | (6,748,159)
​ ​ NOTE H – SEGMENT INFORMATION, continued Reconciliation of loss from segment operations to Corporate (loss) income for the three-month periods ended June 30, 2025 and 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2025 |  | 2024
Loss from operations of reportable segments | ​ | $ | (1,851,367) | ​ | $ | (2,244,206)
General corporate expenses (b) | ​ |  | (1,842,693) | ​ | ​ | (1,102,485)
Interest income | ​ |  | 40,267 | ​ | ​ | 36,295
Unrealized gain on change in fair value of warrants classified as a liability | ​ |  | 6,410 | ​ | ​ | 5,160,000
Net loss from discontinued operations | ​ | ​ | (336,195) | ​ | ​ | —
Other (expense) income, net | ​ |  | (531) | ​ | ​ | (103)
Consolidated net (loss) income | ​ | $ | (3,984,109) | ​ | $ | 1,849,501
​ Reconciliation of loss from segment operations to Corporate loss for the nine-month periods ended June 30, 2025 and 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2025 |  | 2024
Loss from operations of reportable segments |  | $ | (5,364,735) |  | $ | (6,748,159)
General corporate expenses (b) | ​ | ​ | (4,684,821) | ​ | ​ | (4,005,351)
Interest income | ​ | ​ | 168,672 | ​ | ​ | 84,972
Unrealized gain on change in fair value of warrants classified as a liability | ​ | ​ | 318,840 | ​ | ​ | 9,564,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |  | ​ | — |  | ​ | (394,000)
Transaction costs allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | (633,198)
Loss on issuance of warrants | ​ | ​ | — | ​ | ​ | (1,633,767)
Other (expense) income, net |  | ​ | (23,778) |  | ​ | (9,060)
Net loss from discontinued operations | ​ | ​ | (403,120) | ​ | ​ | —
Consolidated net loss | ​ | $ | (9,988,942) | ​ | $ | (3,774,563)
(a) | Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
(b) | General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.
| NOTE K – SEGMENT AND GEOGRAPHIC AREA INFORMATION As detailed in Note C above, the Company has three reportable segments. (1) Therapeutic DNA Production Services (2) MDx Testing Services, and (3)DNA Tagging and Security Products and Services. Resources are allocated by our CEO, COO, CFO and CLO whom, collectively the Company has determined to be our Chief Operating Decision Maker (CODM). Information regarding operations by segment for the twelve- month period ended September 30, 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ | ​ | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 560,000 | ​ | $ | — | ​ | $ | 514,813 | ​ | $ | 1,074,813
Service revenues | ​ |  | 335,354 | ​ | ​ | — | ​ | ​ | 703,323 | ​ | ​ | 1,038,677
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 1,330,850 | ​ | ​ | — | ​ | ​ | 1,330,850
Less intersegment revenues | ​ |  | — | ​ | ​ | (12,920) | ​ | ​ | — | ​ | ​ | (12,920)
Total revenues | ​ | $ | 895,354 | ​ | $ | 1,317,930 | ​ | $ | 1,218,136 | ​ | $ | 3,431,420
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 678,166 | ​ | $ | (49,830) | ​ | $ | 388,543 | ​ | $ | 1,016,879
(Loss) income from segment operations (a) | ​ | $ | (4,789,268) | ​ | $ | (1,489,220) | ​ | $ | (2,551,983) | ​ | $ | (8,830,471)
​ Information regarding operations by segment for the twelve- month period ended September 30, 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ | ​ | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product revenues | ​ | $ | 560,000 | ​ | $ | — | ​ | $ | 658,185 | ​ | $ | 1,218,185
Service revenues | ​ |  | 506,285 | ​ | ​ | — | ​ | ​ | 490,581 | ​ | ​ | 996,866
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 11,253,312 | ​ | ​ | — | ​ | ​ | 11,253,312
Less intersegment revenues | ​ |  | — | ​ | ​ | (100,920) | ​ | ​ | — | ​ | ​ | (100,920)
Total revenues | ​ | $ | 1,066,285 | ​ | $ | 11,152,392 | ​ | $ | 1,148,766 | ​ | $ | 13,367,443
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 748,940 | ​ | $ | 4,409,186 | ​ | $ | 375,306 | ​ | $ | 5,533,432
(Loss) income from segment operations (a) | ​ | $ | (3,792,871) | ​ | $ | 1,206,652 | ​ | $ | (3,550,794) | ​ | $ | (6,137,013)
​ Reconciliation of segment loss from operations to corporate loss: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30,
​ |  | 2024 | ​ | 2023
Loss from operations of reportable segments |  | $ | (8,830,471) |  | $ | (6,137,013)
General corporate expenses (b) | ​ |  | (5,194,294) | ​ |  | (4,816,277)
Interest income | ​ |  | 176,301 | ​ |  | 75,332
Unrealized gain on change in fair value of warrants classified as a liability | ​ | ​ | 9,430,000 | ​ | ​ | —
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | ​ | ​ | (394,000) | ​ | ​ | —
Transaction costs allocated to registered direct offering | ​ | ​ | (633,198) | ​ | ​ | 854,400
Transaction costs allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | —
Loss on issuance of warrants | ​ | ​ | (1,633,767) | ​ | ​ | —
Other income (expense), net | ​ |  | (8,877) | ​ | $ | 642
Consolidated loss before provision for income taxes | ​ | $ | (7,088,306) | ​ | $ | (10,022,916)
(a) | Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
(b) | General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.
​ NOTE K – SEGMENT AND GEOGRAPHIC AREA INFORMATION, continued The Company attributes net revenues from external customers according to the geographic location of the customer. Net revenues by geographic location of customers are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended September 30,
​ |  | 2024 |  | 2023
Americas | ​ | $ | 2,269,826 | ​ | $ | 12,222,650
Europe | ​ |  | 172,368 | ​ | ​ | 258,355
Asia and other | ​ |  | 989,226 | ​ | ​ | 886,438
Total | ​ | $ | 3,431,420 | ​ | $ | 13,367,443
​

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration